The p38 mapk signaling activation in colorectal cancer upon therapeutic treatments

Angelina Pranteda, Valentina Piastra, Lorenzo Stramucci, Deborah Fratantonio, Gianluca Bossi

Research output: Contribution to journalArticlepeer-review


Pharmacological treatment of colorectal carcinoma currently proceeds through the administration of a combination of different chemotherapeutic agents. In the case of rectal carcinoma, radiation therapy also represents a therapeutic strategy. In an attempt at translating much-needed new targeted therapy to the clinics, p38 mitogen activated protein kinase (MAPK) inhibitors have been tested in clinical trials involving colorectal carcinoma patients, especially in combination with chemotherapy; however, despite the high expectations raised by a clear involvement of the p38 MAPK pathway in the response to therapeutic treatments, poor results have been obtained so far. In this work, we review recent insights into the exact role of the p38 MAPK pathway in response to currently available therapies for colorectal carcinoma, depicting an intricate scenario in which the p38 MAPK node presents many opportunities, as well as many challenges, for its perspective exploitation for clinical purposes.

Original languageEnglish
Article number2773
JournalInternational Journal of Molecular Sciences
Issue number8
Publication statusPublished - Apr 2 2020


  • 5-fluorouracil
  • Colorectal cancer
  • Irinotecan
  • Oxaliplatin
  • P38 MAPK
  • Radiotherapy
  • Target therapy
  • Therapeutic treatments

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'The p38 mapk signaling activation in colorectal cancer upon therapeutic treatments'. Together they form a unique fingerprint.

Cite this